• 52,780+ CME Conference Registrations Sold
  • 158,339+ Medical Conferences
  • 285 Specialties
  • 11,430 Organizers
  • 157,205 Speakers
  • 159 Countries
  • 4,804 Cities

Neurology : Rituximab as treatment Infectious Diseaseor anti-MuSK myasthenia gravis: Multicenter blinded prospective review is organized by American Academy of Neurology (AAN) and will be held during Sep 05, 2017 - Sep 05, 2020. This CME Conference has been approved FOR a maximum of 0.75 AMA PRA Category 1 Credits.

Conference Objectives are :
Upon completion of the article by Hehir et al, the participant should be able to:
• State the most common sex and relative age for patients with anti-MUSK myasthenia gravis in study
• State what percentage of rituximab-treated patients in this study met the primary outcome
• State what secondary outcomes from rituximab treatment were met during this review

Additional details will be posted as soon as they are available.

Intended Audience

Rheumatology, Medicine

Activity Payment Details

Activity Fee : NA
Interested

Rate this CME (Min 1 - Max 5)

Duration:
Fee and expenses:
CME credits:
Program contents:
Networking:
Write Your Review

Reviews Given by Professionals

No Reviews available. Be the first to write a review.

Privacy Policy

Read eMedEvents Privacy Policy

Organizer(s)

American Academy of Neurology (AAN)

View Organizer Details

Help

(800) 879-1960, (612) 928-6000

Convert
Live to Virtual Conference

Market your online event to Million plus Healthcare professionals.